Edesa Biotech
EDSA
10 hedge funds and large institutions have $74K invested in Edesa Biotech in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.02% more ownership
Funds ownership: 0% → 0.02% (+0.02%)
17% less funds holding
Funds holding: 12 → 10 (-2)
20% less capital invested
Capital invested by funds: $93K → $74K (-$19K)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$51.4K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$49.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$31.8K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$1K |
| 5 |
AWM
Avior Wealth Management
Omaha,
Nebraska
|
+$143 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$49K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19K |
| 3 |
VF
Virtu Financial
New York
|
-$9K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$1K |
| 5 |
WAS
WESPAC Advisors SoCal
Pasadena,
California
|
-$1K |
EDSA Hedge Fund Activity: Q2 2018 in Review
10 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q2 2018, worth a combined $74K — down 20% from $93K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of EDSA and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Raymond James Financial Services Advisors, opening a new position worth an estimated $51.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $49K sold.
- 10 institutional investors held Edesa Biotech (EDSA) as of Q2 2018, down from 12 in Q1 2018.
- Funds reported $74K of Edesa Biotech stock for Q2 2018, down 20% quarter-over-quarter.
- 3 funds opened new Edesa Biotech positions in Q2 2018 and 5 closed out, a net change of -2 holders.
- The largest Edesa Biotech buyer in Q2 2018 was Raymond James Financial Services Advisors, an estimated $51.4K added.
- The largest Edesa Biotech seller in Q2 2018 was Citadel Advisors, an estimated $49K sold.
Based on aggregated 13F filings for Q2 2018.